Home Featured 2

Featured 2

Featured posts

Random

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

lungcanc

Potential Improvement in Lung Cancer Deaths and Overall Mortality With Integration of Smoking Cessation and Lung Cancer Screening

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer

A Roadmap to Improving Lung Cancer Care in the Middle East and North Africa

Consolidating Gains with Chemotherapy in SCLC Maintenance Trials: A Discussion with...

lungcanc

Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis,...

lungcanc

Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint...

lungcanc

IASLC Journals Share Exciting Milestones on Metrics Journeys

lungcanc

Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A...

lungcanc

Time to End the Debate on Genomic Testing in NSCLC

lungcanc

Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and...

lungcanc

Smoking Cessation After Cancer Diagnosis: A Neglected Problem

lungcanc

TTFields in Unresectable MPM: STELLAR Results in Practice

lungcanc

On the Backs of Specialists: LDCT Screening Has Heightened the Importance...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib